Literature DB >> 20926297

Surgical management of large solid hemangioblastomas of the posterior fossa.

Jie-Qing Wan1, Hua Cui, Yong Wang.   

Abstract

From January 2000 to January 2009, 15 patients presented with large solid hemangioblastomas of the posterior fossa; eight of these patients were also diagnosed with von Hippel-Lindau (VHL) disease. Diagnostic imaging showed large vascular lesions. All 15 patients underwent surgery through a suboccipital ipsilateral, modified far-lateral, suboccipital midline or suboccipital supracerebellar approach. Preoperative embolization was attempted in seven patients. Complete removal of the tumor was performed in all patients. An overall neurological improvement was observed in 11 of the 15 patients, corresponding to 61.5%. During follow-up, six patients, all with VHL disease, developed recurrence. Two patients died of renal cell carcinoma after 1 year. Our favorable outcomes suggest that surgical resection is the optimal treatment for patients with large solid hemangioblastomas of the posterior fossa. With improved microsurgical techniques and a better understanding of the vascular pattern of this type of tumor, total microsurgical removal can be performed with low mortality. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 20926297     DOI: 10.1016/j.jocn.2010.07.099

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  11 in total

1.  Selection of surgical approach for cerebellar hemangioblastomas based on venous drainage patterns.

Authors:  Takashi Watanabe; Yuuki Suematsu; Kiyotaka Saito; Go Takeishi; Shinji Yamashita; Hajime Ohta; Kiyotaka Yokogami; Hideo Takeshima
Journal:  Neurosurg Rev       Date:  2021-04-20       Impact factor: 3.042

2.  Growth rate and fate of untreated hemangioblastomas: clinical assessment of the experience of a single institution.

Authors:  Joonho Byun; Hee Jun Yoo; Jeong Hoon Kim; Young Hoon Kim; Young Hyun Cho; Seok Ho Hong; Chang Jin Kim
Journal:  J Neurooncol       Date:  2019-06-14       Impact factor: 4.130

3.  Surgical management of medulla oblongata hemangioblastomas in one institution: an analysis of 62 cases.

Authors:  Xuesong Liu; Yuekang Zhang; Xuhui Hui; Chao You; Fang Yuan; Wenjing Chen; Si Zhang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 4.  Contiguous haemangioblastomas of the brain and spine in a patient of Von Hippel-Lindau disease.

Authors:  Asifur Rahman; Saif Ul Hoque; Paawan Bahadur Bhandari; Shamsul Alam
Journal:  BMJ Case Rep       Date:  2013-01-22

5.  Surgical resection of cerebellar hemangioblastoma with enhanced wall thickness: A report of two cases.

Authors:  Zhenxing Sun; Dan Yuan; Yaxing Sun; Pengxiang Yan; Huancong Zuo
Journal:  Oncol Lett       Date:  2015-02-10       Impact factor: 2.967

6.  [Hemangioblastomas of the posterior fossa: Report of 16 cases and literature review].

Authors:  Alvaro Campero; Pablo Ajler; Julio Fernandez; Gustavo Isolan; Martin Paiz; Conrado Rivadeneira
Journal:  Surg Neurol Int       Date:  2016-11-21

7.  Surgical treatment of cerebellar hemangioblastomas.

Authors:  A Cervio; J F Villalonga; R Mormandi; S Condomí Alcorta; G Sevlever; J Salvat
Journal:  Surg Neurol Int       Date:  2017-08-01

8.  Surgical treatment of solid hemangioblastomas of the posterior fossa: A report of 28 cases.

Authors:  Hua Cui; Jian Zou; Ying-Hui Bao; Ming-Sheng Wang; Yong Wang
Journal:  Oncol Lett       Date:  2016-12-23       Impact factor: 2.967

9.  A Rare Case of Giant Solid Hemangioblastoma Accompanied with Hemophilia Type A.

Authors:  Masaki Ujihara; Yoshinori Maki; Masaki Chin; Kensuke Takada; Yoshitaka Kurosaki; Sen Yamagata
Journal:  NMC Case Rep J       Date:  2018-09-13

10.  Craniotomy for cerebellar hemangioblastoma excision in a patient with von Hippel-Lindau disease complicated by uncontrolled hypertension due to pheochromocytoma.

Authors:  Yoshifumi Mizobuchi; Teruyoshi Kageji; Yamaguchi Tadashi; Shinji Nagahiro
Journal:  Int J Surg Case Rep       Date:  2015-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.